Cocrystal Discovery focuses on discovering and developing novel antiviral therapeutics that inhibit viral replication enzymes, with programs targeting hepatitis C, influenza and rhinovirus. The company employs atomic-level structure determination, including high-resolution X-ray crystallography, combined with advanced computational methods to design first- and best-in-class small-molecule inhibitors. CDI is developing oral, once-a-day, broad-spectrum antivirals aimed at treating serious and chronic viral diseases. The company is privately funded and will use the incoming investment to continue its development programs. CDI’s stated mission is to discover and develop oral inhibitors of the viral replication complex and to expand its platform to address viral and other diseases. Headquarters are in Bothell, Washington, with laboratories in Bothell and Mountain View, California.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2011